Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
We investigated, in the protease and GAG cleavage sites, the role of minority populations on the evolution of resistance to a subsequent boosted protease inhibitor (PI) regimen after a first failure to nelfinavir. Two pathways were observed: the addition of mutations to a currently dominant genotype when minority variants are not shown, or the emergence of a minority variant as a dominant strain. These minor species, not detected by standard genotype, may influence PI susceptibility.
Roquebert
Bénédicte
B
Department of Virology, Pitié-Salpêtrière Hospital, Paris, France.
Malet
Isabelle
I
Wirden
Marc
M
Tubiana
Roland
R
Valantin
Marc-Antoine
MA
Simon
Anne
A
Katlama
Christine
C
Peytavin
Gilles
G
Calvez
Vincent
V
Marcelin
Anne-Geneviève
AG
D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D019143:Evolution, Molecular; D015683:Gene Products, gag / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019888:Nelfinavir / Q000627:therapeutic use; D017211:Treatment Failure
D015683:Gene Products, gag; D017320:HIV Protease Inhibitors; D016333:HIV Protease; D019888:Nelfinavir